Login / Signup

Characterization of colorectal cancer by hierarchical clustering analyses of five immune cell markers.

Sunao ItoAkira KoshinoMasayuki KomuraShunsuke KatoTakahiro OtaniChengbo WangAkane UekiHiroki TakahashiMasahide EbiNaotaka OgasawaraToyonori TsuzukiKenji KasaiKunio KasugaiShuji TakiguchiSatoru TakahashiShingo Inaguma
Published in: Pathology international (2023)
The present study analyzed the expression of five independent immunohistochemical markers, CD4, CD8, CD66b, CD68, and CD163, on immune cells within the colorectal cancer (CRC) tumor microenvironment (TME). Using hierarchical clustering, patients were successfully classified according to significant associations with clinicopathological features and/or survival. Patients with mismatch repair-proficient (pMMR) CRC were categorized into four groups with survival differences (p = 0.0084): CD4 Low , CD4 High , MΦ High , and CD8 Low . MΦ High tumors showed significantly higher expression of CD47 (p < 0.0001), a phagocytosis checkpoint molecule. These tumors contained significantly greater numbers of PD-1+ (p < 0.0001), TIM-3+ (p < 0.0001), and SIRPA+ (p < 0.0001) immune cells. Notably, 10% of the patients with pMMR CRC expressed PD-L1 (CD274) on tumor cells with significantly worse survival (p = 0.00064). The Cox proportional hazards model identified MΦ High (hazard ratio [HR] = 2.02, 95%, p = 0.032), CD8 Low (HR = 2.45, p = 0.011), and tumor PD-L1 expression (HR = 2.74, p = 0.0061) as potential risk factors. PD-L1-PD-1 and/or CD47-SIRPA axes targeting immune checkpoint therapies might be considered for patients with pMMR CRC according to their tumor cells and tumor immune microenvironment characteristics.
Keyphrases
  • nk cells
  • risk factors
  • stem cells
  • poor prognosis
  • end stage renal disease
  • chronic kidney disease
  • newly diagnosed
  • risk assessment
  • single cell
  • drug delivery
  • cell cycle
  • free survival